The global hemophilia treatment market is on a strong growth trajectory, with projections indicating a rise from USD 12.1 billion in 2024 to a remarkable USD 18.7 billion by 2034. This growth, driven ...

The Cybersecurity and Global Policy Program is co-led by Isak Nti Asare, assistant dean of undergraduate education and ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

We explore key trends from HID Global's 2025 State of Security and Identity report, with additional insights from Memoori ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Trends in cybersecurity across 2024 showed less malware and phishing, though more social engineering. CrowdStrike offers tips on securing your business.

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

As World Tuberculosis Day on March 24, 2025, approaches, global health authorities yet again find themselves at a crucial juncture in efforts to tackle the continuing global emergency of tuberculosis.

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s MHLW for use in conjunction with VRd to treat newly diagnosed ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral ...

BNY Mellon Global Equity Income Fund underperformed its benchmark index, the FTSE World Index, during the fourth quarter of ...